Related Experiment Video
Updated: Jul 13, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
[Doubts as to the cardiovascular safety of rosiglitazone]
J B L Hoekstra1, P M M Bossuyt, J H de Vries
1Academisch Medisch Centrum/Universiteit van Amsterdam, Postbus 22.660, 1100 DD Amsterdam. j.b.hoekstra@amc.uva.nl
Abstract:
Recently, it was observed that rosiglitazone increased the risk of myocardial infarction. The American Food and Drug Administration therefore issued a safety alert. The practice guideline 'Diabetes mellitus type 2' of the Dutch College of General Practitioners only leaves room for the use of another thiazolidinedione, pioglitazone, and even that advice has been questioned. The new information on the serious adverse effects of rosiglitazone may further reduce the willingness to prescribe this drug for patients with type 2 diabetes.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Hypoglycemia and Glucagon
Hyperglycemia
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
